In a report released today, Benjamin Budish from Barclays assigned a Hold rating to Certara (CERT – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $16.88.
According to TipRanks, Budish is a 4-star analyst with an average return of 10.4% and a 71.43% success rate. Budish covers the Financial sector, focusing on stocks such as Coinbase Global, Charles Schwab, and Blackstone Group.
Certara has an analyst consensus of Hold, with a price target consensus of $18.00, which is a 6.64% upside from current levels. In a report released on February 26, Leerink Partners also initiated coverage with a Hold rating on the stock with a $19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.96 and a one-year low of $11.81. Currently, Certara has an average volume of 572.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara (CERT) Company Description:
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
- Certara Reports Fourth Quarter 2023 Financial Results
- Certara initiated with a Market Perform at Leerink
- Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
- Certara price target raised to $18 from $16 at Barclays
